Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy.
Saved in:
| Title: | Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. |
|---|---|
| Authors: | Oura M; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Toho M; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Ikeda D; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Fukuda N; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Torres AS; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Fujii F; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Sakuma H; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Uehara A; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Tabata R; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Narita K; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Takeuchi M; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan., Matsue K; Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Mar 12; Vol. 16, pp. 1738551. Date of Electronic Publication: 2026 Mar 12 (Print Publication: 2026). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
